These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 29230420)

  • 1. Glycaemic Control after Metformin Discontinuation in Diabetic Patients with a Declining Renal Function.
    Leyco T; Ryanputra D; Peh R; Ponce A; Khoo CM
    J Diabetes Res; 2017; 2017():2769819. PubMed ID: 29230420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of metformin in type 2 diabetes patients treated with insulin.
    Wulffelé MG; Kooy A; Lehert P; Bets D; Oom JA; Borger van der Burg B; Donker AJ; Stehouwer CD
    Neth J Med; 2002 Jul; 60(6):249-52. PubMed ID: 12365468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
    Sipahi S; Solak Y; Acikgoz SB; Genc AB; Yildirim M; Yilmaz U; Nalbant A; Tamer A
    Int Urol Nephrol; 2016 Aug; 48(8):1305-1312. PubMed ID: 27102431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.
    Cai XL; Chen YL; Zhao JJ; Shan ZY; Qiu MC; Li CJ; Gu W; Tian HM; Yang HZ; Xue YM; Yang JK; Hong TP; Ji LN
    Chin Med J (Engl); 2015 May; 128(10):1279-87. PubMed ID: 25963345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using continuous glucose monitoring to assess contributions of premeal and postmeal glucose levels in diabetic patients treated with metformin alone.
    Lin SD; Su SL; Wang SY; Tu ST; Hsu SR
    Diabetes Metab; 2016 Nov; 42(5):336-341. PubMed ID: 27068362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients.
    Lunetta M; DiMauro M
    Diabetes Res Clin Pract; 1996 Jun; 33(1):53-8. PubMed ID: 8877276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
    Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
    J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Dargie H; Komajda M; Gubb J; Biswas N; Jones NP
    Diabetologia; 2005 Sep; 48(9):1726-35. PubMed ID: 16025252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin monotherapy for type 2 diabetes mellitus.
    Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
    Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.